Protein Fluidics
Automated assay system for 3D cell models to maintain the 3D cells and allow for easy media, or reagent exchanges.
| Date | Investors | Amount | Round |
|---|---|---|---|
* | N/A | - | |
| Total Funding | 000k | ||
Related Content
Protein Fluidics, founded in 2015 by Dr. Evan F. Cromwell, operates within the life sciences and healthcare sectors, specializing in the development of biological assay automation platforms. Dr. Cromwell, who serves as President and CEO, is a serial entrepreneur with a Ph.D. in Physical Chemistry from the University of California, Berkeley. His journey into this venture began after meeting a colleague with a new microfluidic technology, leading him to leverage his extensive experience in developing analytical systems to address the growing need for three-dimensional cell models in research.
The company's core business revolves around commercializing automation platforms that utilize novel microfluidic technologies to accelerate data-driven decisions for scientists. Its primary clients include research hospitals, academic institutions, and pharmaceutical companies. The business model is centered on the sale of its proprietary systems and associated consumables. Based in the San Francisco Bay Area, the privately held company is venture capital-backed, having completed multiple funding rounds, including a Series B in July 2018.
Protein Fluidics' flagship product is the Pu•MA System, a benchtop instrument designed to automate assays for 3D cell models like organoids, spheroids, and tumoroids. The system works in conjunction with disposable Flowchips, which use a patented Valve-less Fluidic Switching (VLFS) technology to precisely manage the exchange of liquids such as media, metabolites, or reagents. This automation minimizes manual handling, reduces the risk of damaging the delicate 3D cell structures, and allows the system to run complex, pre-loaded protocols inside a standard cell culture incubator to maintain physiological conditions. Key applications for the Pu•MA System include immunofluorescence staining, immune cell co-cultures, toxicity testing, and metabolomic profiling, primarily serving research in oncology, neuroscience, and drug discovery.
Keywords: biological assay automation, microfluidics, 3D cell models, organoid assays, spheroid assays, PuMA System, life sciences tools, laboratory automation, drug discovery, oncology research, neuroscience research, toxicity testing, Evan F Cromwell, Valve-less Fluidic Switching, Flowchips, cell-based assays, preclinical research, tumoroids, immunofluorescence staining, supernatant sampling